Nov 1, 2024, 17:46
Hidehito Horinouchi: Early Stage NSCLC at ACLC24 session
Hidehito Horinouchi, Assistant Chief of the National Cancer Center Hospital, shared a post on X:
“ACLC24 IASLC Asia.
ES12: Early Stage NSCLC: Adjuvant/Neoadjuvant Immunotherapy, Targeted Therapy
- Chairs: Tetsuya Mitsudomi and Heather Wakelee.
- Speaker: Hidehito Horinouchi.
- Topic: Significance of MRD for Optimizing Perioperative Treatment.”
More posts featuring Hidehito Horinouchi.
Hidehito Horinouchi is the Assistant Chief of the National Cancer Center Hospital. He also serves as the Secretary General of the Lung Cancer Study Group, Japan Clinical Oncology Group, and the Deputy Chief of the Center for Education and Professional Career Development at the National Cancer Center Hospital.
He specializes in multimodal treatment strategies, including medical, surgical, and radiation oncology, for patients with thoracic malignancies.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 3, 2024, 05:43
Dec 3, 2024, 05:40
Dec 3, 2024, 05:36
Dec 3, 2024, 05:11
Dec 3, 2024, 05:06
Dec 3, 2024, 05:01
Dec 3, 2024, 04:55
Dec 3, 2024, 04:51
Dec 3, 2024, 03:59
Dec 3, 2024, 03:53
Dec 3, 2024, 03:41